据招股书数据，泰德医药近几年营收分别为3.51亿元、3.37亿元和4.42亿元，展现出强劲势头。其背后 是多元化的客户结构与全球化布局的支撑，目前，企业客户覆盖全球50多个国家，美国、中国内地、日 本和欧洲的营收分别占比55%、21.4%、7.1%和11%。较为分散的市场分布有效对冲了依靠单一市场的 风险。 本文源自：智通财经网 智通财经获悉，泰德医药(03880)早盘涨超9%，高见40.54港元，刷新上市新高。截至发稿，涨8.9%，报 40.14港元，成交额2103.22万港元。 消息面上，泰德医药将于8月29日召开董事会会议以审批中期业绩。根据弗若斯特沙利文的资料，于 2023年，按销售收入计，泰德医药是全球第三大专注于多肽的CRDMO，市场份额为1.5%。公司提供从 早期发现、临床前研究及临床开发以至商业化生产的全周期服务。全球专注于多肽的CRDMO市场的两 大参与者占23.8% 的市场份额，其余市场参与者则较为分散，2023年第三至六大参与者(包括本公司)分 别仅占约1%的市场份额。 ...

Core Viewpoint - 泰德医药's stock price increased over 9%, reaching a new high of 40.54 HKD, driven by positive market sentiment ahead of its upcoming board meeting to approve mid-term results [1] Company Summary - 泰德医药 is the third largest global player in the peptide-focused CRDMO market, holding a market share of 1.5% as of 2023, according to Frost & Sullivan [1] - The company offers a full-cycle service from early discovery, preclinical research, clinical development to commercial production [1] - The top two players in the global peptide-focused CRDMO market account for 23.8% of the market share, while the remaining participants, including 泰德医药, hold approximately 1% each [1] Financial Performance - 泰德医药's revenue for the past few years has shown strong momentum, with figures of 351 million, 337 million, and 442 million CNY [1] - The company's diverse client base and global presence support its growth, with clients across over 50 countries [1] - Revenue distribution is as follows: 55% from the United States, 21.4% from mainland China, 7.1% from Japan, and 11% from Europe, indicating a well-distributed market presence that mitigates risks associated with reliance on a single market [1]

Core Viewpoint - 泰德医药's stock price increased over 9%, reaching a new high of 40.54 HKD, driven by positive market sentiment ahead of its upcoming board meeting to approve mid-term results [1] Company Summary - 泰德医药 is the third largest global player in the peptide-focused CRDMO market, holding a market share of 1.5% as of 2023, according to Frost & Sullivan [1] - The company offers a full-cycle service from early discovery, preclinical research, clinical development to commercial production [1] - The top two players in the global peptide-focused CRDMO market account for 23.8% of the market share, while the remaining participants are more fragmented, with the third to sixth largest players, including 泰德医药, each holding approximately 1% market share [1] Financial Performance - 泰德医药's revenue for the past few years has shown strong momentum, with figures of 351 million, 337 million, and 442 million CNY [1] - The company's diverse client base and global presence support its growth, with clients spanning over 50 countries [1] - Revenue distribution is as follows: 55% from the United States, 21.4% from mainland China, 7.1% from Japan, and 11% from Europe, indicating a well-diversified market presence that mitigates risks associated with reliance on a single market [1]